Finally, as we found that only IDH1 and SETD2 mutations were identified as potential genomic drivers of CIMP across more than two cancer types, we investigated whether there might be small groups of patients presenting mutations in IDH1 or SETD2 correlated with hypermethylation that would remain undetected by our method. Here, IDH1 is linked to cancer.